NURS 615 Exam 3 2026 | Advanced Pharmacology Questions, Answers & Detailed Rationales | NP Study Guide

NURS 615 xx




Exam 3 2026 | Practice Questions, Answers & Detailed
xx xx xx xx xx xx xx xx




Rationales | Advanced Pharmacology Exam Prep
xx xx xx xx xx xx




Resource Features xx




➢ NURS 615 Exam 3 practice questions
xx xx xx xx xx




➢ Detailed answers xx




➢ Comprehensive rationales xx




➢ Pharmacology scenarios xx




➢ Prescribing case studies xx xx

, NURS 615 Exam 3 2026 | Practice Questions, xx xx xx xx xx xx xx




Answers & Detailed Rationales | Advanced
xx xx xx xx xx xx




xx Pharmacology Exam Prep xx xx




1. Low-dose colchicine for gout flare:
xx xx xx xx xx




• A) 1.2 mg once daily for 7 days
xx xx xx xx xx xx xx




• B) 1.2 mg at first sign of flare, followed by 0.6 mg one hour
xx xx xx xx xx xx xx xx xx xx xx xx xx




later for a total dose of 1.8 mg
xx xx xx xx xx xx xx xx




• C) 0.6 mg every 4 hours for 24 hours
xx xx xx xx xx xx xx xx




• D) 1.2 mg twice daily for 3 days
xx xx xx xx xx xx xx




Answer: B) 1.2 mg at first sign of flare, followed by 0.6 mg one
xx xx xx xx xx xx xx xx xx xx xx xx xx




xx hour later for a total dose of 1.8 mg
xx xx xx xx xx xx xx xx




Rationale: The FDA-approved low-dose colchicine regimen for acute gout
xx xx xx xx xx xx xx xx




flare is 1.2 mg at onset, followed by 0.6 mg one hour later (total 1.8 mg).
xx xx xx xx xx xx xx xx xx xx xx xx xx xx xx xx




This regimen is preferred over high-dose protocols due to reduced
xx xx xx xx xx xx xx xx xx xx




gastrointestinal toxicity while maintaining efficacy. Patients should start at
xx xx xx xx xx xx xx xx xx




the earliest sign of a flare, ideally within 12-24 hours.
xx xx xx xx xx xx xx xx xx xx




2. High-dose colchicine regimen:
xx xx xx




• A) 1.2 mg followed by 0.6 mg every 4-6 hours totaling 4.8 mg
xx xx xx xx xx xx xx xx xx xx xx xx




• B) 0.6 mg every 2 hours for 12 hours
xx xx xx xx xx xx xx xx




• C) 1.2 mg three times daily
xx xx xx xx xx




• D) 0.6 mg every 8 hours
xx xx xx xx xx

,Answer: A) 1.2 mg followed by 0.6 mg every 4-6 hours totaling 4.8
xx xx xx xx xx xx xx xx xx xx xx xx




xx mg

Rationale: The traditional high-dose colchicine regimen (1.2 mg followed
xx xx xx xx xx xx xx xx




by 0.6 mg every 4-6 hours up to 4.8 mg) is no longer recommended due
xx xx xx xx xx xx xx xx xx xx xx xx xx xx xx




to increased toxicity without additional benefit. The low-dose regimen is
xx xx xx xx xx xx xx xx xx xx




preferred. GI toxicity is dose-dependent; high-dose significantly increases
xx xx xx xx xx xx xx xx




diarrhea and vomiting.
xx xx xx




3. In the treatment of gout, which labs should be monitored?
xx xx xx xx xx xx xx xx xx xx




• A) BUN, creatinine, and creatinine clearance
xx xx xx xx xx




• B) Liver function tests only
xx xx xx xx




• C) Complete blood count only
xx xx xx xx




• D) Electrolytes only
xx xx




Answer: A) BUN, creatinine, and creatinine clearance
xx xx xx xx xx xx




Rationale: Gout medications (especially colchicine, allopurinol, and
xx xx xx xx xx xx




febuxostat) are excreted renally and can cause nephrotoxicity. Baseline
xx xx xx xx xx xx xx xx xx




and periodic renal function assessment (BUN, creatinine, creatinine
xx xx xx xx xx xx xx xx




clearance) is essential for safe dosing and monitoring. Dose adjustments
xx xx xx xx xx xx xx xx xx xx




are required for patients with renal impairment.
xx xx xx xx xx xx xx




4. Colchicine can cause which adverse effects?
xx xx xx xx xx xx




• A) Severe diarrhea, nausea, vomiting, abdominal pain
xx xx xx xx xx xx

, • B) Severe headache and dizziness
xx xx xx xx




• C) Rash and pruritus
xx xx xx




• D) Nephrotoxicity only
xx xx




Answer: A) Severe diarrhea, nausea, vomiting, abdominal pain
xx xx xx xx xx xx xx




Rationale: Colchicine's most common side effects are gastrointestinal:
xx xx xx xx xx xx xx




severe diarrhea, nausea, vomiting, and abdominal pain. These symptoms
xx xx xx xx xx xx xx xx xx




often occur at therapeutic doses and may limit use. GI toxicity is dose-
xx xx xx xx xx xx xx xx xx xx xx xx xx




dependent and more prominent with high-dose regimens. Patients should
xx xx xx xx xx xx xx xx




be educated to report severe GI symptoms, which may indicate toxicity.
xx xx xx xx xx xx xx xx xx xx xx




5. Febuxostat (Uloric): When prescribing this medication, patients
xx xx xx xx xx xx xx




xx should be taught that: xx xx xx




• A) Gout will resolve immediately
xx xx xx xx




• B) Gout may worsen with therapy before it improves
xx xx xx xx xx xx xx xx




• C) No follow-up is needed
xx xx xx xx




• D) It does not affect uric acid levels
xx xx xx xx xx xx xx




Answer: B) Gout may worsen with therapy before it improves
xx xx xx xx xx xx xx xx xx




Rationale: Febuxostat, a xanthine oxidase inhibitor, rapidly lowers uric acid
xx xx xx xx xx xx xx xx xx




levels. This sudden drop can mobilize urate deposits, triggering acute
xx xx xx xx xx xx xx xx xx xx




gout flares. Patients should continue therapy during flares; anti-
xx xx xx xx xx xx xx xx xx




inflammatory prophylaxis (colchicine or NSAIDs) is often co-administered
xx xx xx xx xx xx xx




for the first 3-6 months.
xx xx xx xx xx